To evaluate efficacy and safety of endovascular occlusion of left atrial appendage (LAA) with Watchman device in patients, contraindicated for long-term anticoagulant therapy Methods and Results. Watchman device implantation performed in 37 patients with non-valvular AF, CHA2DS2VASc score >2 (mean 4.73±1.15), HAS-BLED>3 (mean 3.84±0.76), with contraindications for long-term anticoagulation therapy, with > 6 months follow-up period. Technical success was achieved in 94.6% (35 patients). Periprocedural complications were device embolization in 1 patient and pericardial effusion, requiring treatment. During 14.8±6.7 months follow-up neither haemorrhagic/ischemic stokes or TIA were observed. Conclusion. The LAA occlusion with Watchman device can be safely performed in selected patients with contraindications to oral anticoagulation (OAC). Atrial fibrillation, Left atrial appendage closure, Watchman device.
Introduction

A
trial Fibrillation (AF) is the most common rhythm disorder with clinical symptoms and the number of affected patients enlarges every year 1 . Ischemic events are the most dangerous complications of AF, neurological disorders and deficits are more severe than those outcoming from non-AF stroke 2 , and ischemic stroke associated with AF are nearly twice as likely to be fatal as non-AF stroke 3 . Anticoagulation therapy is recommended to all AF patients with high individual risk of ischemic complications, also in the case of successful cardioversion. Major bleeding is a serious complication in patients undergoing anticoagulant therapy, more frequent for elderly people 4 . 10% of AF patients have contraindications for anticoagulation therapy because of the high risk of bleeding 5 and optimal therapeutic range of the anticoagulant therapy is achieved only in 50% of the patients 6 . Endovascular occlusion of LAA, as the main place of life threatening thrombus formation during non-valvular AF, is an alternative, save and effective method of thromboembolic events prophylactic in patients, contraindicated for anticoagulation therapy.
In the article we present our experience in LAA occlusion with Watchman device for the patients with non-valvular AF and contraindications for life-long anticoagulation therapy.
Methods
In Krasnoyarsk Regional Clinical hospital 59 patients with AF and with high individual risk of stroke (CHA2D-S2VASc>2) and high risk of bleeding complications (HAS-BLED>3) were examined as a candidates for LAA occlusion with Watchman device. All patients had co ntra in di cations for long-term anticoagulant therapy. TEE echo was performed in all cases to exclude LA or LAA thrombus, to evaluate LAA and intraatrial septum anatomy. In 1 patient there was a need for computed tomography, for precise evaluation of LAA anatomy. In 5 cases implantation of Watchman device was not possible due to anatomical characteristics. 2 patients had LAA consisted from 2 big lobes, in 1 patient LAA ostium . Eventually 54 patients were scheduled for the LAA closure procedure. We perform the analysis of 37 patients, with >6 months follow-up period.
In our clinic we perform the procedure under general anaesthesia, with TEE and fluoroscopic control. In the case of presence persistent foramen ovale or atrial septal defect it was used for septal crossing, without septal puncture. Implantation was considered successful, if Watchman device was implanted to LAA with total exclusion of LAA from blood circulation and absence of significant residual flow around device. All adverse events during procedure, hospitalisation and follow-up period were registered.
If the patient was on warfarin before the procedure, it was cancelled 4 days before the implantation with transmission on LMH. If the patient was on clopidogrel, it was not cancelled. In the case of absence of anticoagulant or antithrombotic treatment, loading dose of clopidogrel was administered on the day of procedure, after implantation and control TTE in the evening time, with transmission to 75 mg of clopidogrel next day. On the day of procedure heparin was administered intravenously in a weight dose 100 U/kg after transseptal puncture or crossing to LA, to achieve recommended activated clotted time (ACT) 200-300 seconds. Every 30 minutes ACT control was performed, if it was less then 200 seconds additional boluses of intravenous heparin were administrated. Further anticoagulation regime was administrated individually for each patient, according to recommended protocols, eligibility or contraindications for treatment, possibility of INR checking. TTE was performed 6-12 hours after the procedure and before patient's discharge.
After device implantation, patients were followed up at 3, 6, 12 months and once a year after 12th months by phone call. In the case of necessity hospital visit was administrated. Control TEE was performed at 6-8 weeks after the implantation, 6 months and in selected cases 12 months after the procedure to assess device position, residual peri-device flow and device-related thrombus. After total endothelisation, absence of thrombus and peri-device flow warfarin/clopidogrel was cancelled, while aspirin treatment stayed life-long.
Results
The mean age of patients was 65.0±7 years, 20 from 37 (54%) were females (Table 1 ). Attempt to implant Watchman device was performed in 37 patients. In 35 cases procedure was successful (Table 2 ). In one case Watchman device was not implanted due to anatomical characteristics (multi lobes anatomy, not possible to precise evaluation by TEE). One case of device embolization occurred. Mean CHA 2 DS 2 VASc score was 4.73±1.15, so the risk of stroke in analysed group was very high. 70.3% of patients had stroke previously; 18.9% had TIA; 5,4% had systemic thromboembolism (thromboembolism of brachial artery, with surgical intervention). More than half of these patients with adverse thromboembolic events took warfarin, with adequate INR level 2-3 with 60-80% therapeutic range.
Serious device and procedure related events occurred in 2 cases (5.4%). In one case device embolization was observed, after device releasing from delivery system, in spite of satisfactory compression on TEE, and tug-test both on TEE and angiogram. Watchman device migrated to LV, where it fixed in posterior mitral leaflet chords. Patient was send to surgery. Device was retrieved and MACE procedure was performed. 2 weeks after patient was discharged from hospital in sinus rhythm with low dose of antiarrhythmic drugs. In a second case, LA perforation with delivery system hap- pened, operator made a decision to finish implantation of 33 mm Watchman occluder. Pericardial centesis was performed, 400 cc of blood was evacuated. Two days after patient was transferred from ICU to cardiology department, discharged 7 days after without complains. All patients, that underwent implantation procedure where available for follow up. TEE was performed 6-8 weeks after the procedure and in 6 months. In 1 case residual flow (3 mm) persisted after 7 weeks from implantation, 6 months later residual flow was not observed (Figure 1 ). No cases of device embolization or thrombosis in post-operative period were observed.
Annual ischemic stroke rate was expected to be 6.1%, based on CHA 2 DS 2 VASc score between patients in analyzed group. During 14.8±6.7 months follow-up period none of haemorrhagic/ischemic stokes or TIA were observed. During long-term follow up period 5 patients overcame open surgery, 2 patients now get combined treatment of oncological process (laringeal cancer, gastric cancer) The procedure of LAA closure, performed timely, dramatically decreased possible adverse thromboembolic events between these patients.
Discussion
In a group of the patients with non valvular AF, lifethreating thrombus, causing stroke/TIA or systemic thromboembolism are formed in LAA in 90% of the cases 7 . Anticoagulant treatment is necessary for ischemic events prophylactic, but bleeding complications reduce frequency of admission of these treatment. Endovascular methods of LAA occlusion, as the main place of thrombus formation, got their fast development as a prophylactic method, with potentially lower risk of bleedings development.
Several devices for LAA occlusion are aloud to use in clinical practice. In Krasnoyarsk Regional Hospital we implant "Watchman LAA occlusion device" (Boston Scientific, USA), as the most examined, with efficacy, proved in several big randomised studies.
PROTECT-AF study, the only available randomized study, proved the efficacy of Watchman device, by demonstrating the noninferiority of the device-based prophylactic against standard anticoagulant therapy with warfarin. In additional safety end-points more adverse events were fixed in patients, undergoing device implantation -5.5% 8 . In our clinical practice device-related safety events were observed in the same level -5.4% (one device embolization with a need for surgical operation and one pericardial effusion due to LAA perforation). Significant decline in device/procedure related events with operator's experience was shown in CAP Registry (nonrandomized registry of patients undergoing Watchman implantation 9 .
In an ESC Guidelines for the management of atrial fibrillation 2012, LAA percutaneous closure in patients with high stroke risk and contraindications for longterm oral anticoagulation has IIb class of recommendations and B level of evidence
10
. In ESC/EACTS Guidelines on myocardial revascularization 2014 percutaneous LAA closure and antiplatelet therapy is also recommended as a possible strategy in the patients with AF undergoing PCI in a case of high stroke risk and contraindications for long-term combined antiplatelet and anticoagulation therapy (Class IIb, Level of Evidence B)
11
. (Figure 2 a,b,c) . In AHA/ASA Guidelines for the Primary Prevention of Stroke 2014 for the same group of patients it is recommended to perform LAA occlusion in a centre with low rates of periprocedual complications, and added that patient should tolerate the risk of at least 45 days of postprocedual anticoagulation (Class IIb; Level of Evidence B)
.
Data of 4-year follow-up of the PROTECT-AF study have demonstrated statistically significant all-cause death reduction in the Watchman group compared to the control group due to reduction of the haemorrhagic strokes (0.4% vs 2.9% in a patients on warfarin, p<0.001) 13 . TM LAA Closure Technology is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: are at increased risk for stroke and systemic embolism based on CHADS 2 or CHA 2 DS 2 -VASc scores and are recommended for anticoagulation therapy; are deemed by their physicians to be suitable for warfarin; and have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.
Based on this results, in
The decision about method of ischemic events prophylactic for the patients with non-valvular AF should be taken individually for each patient, after precise analysis of potential risks of medicament strategies and innovative endovascular technologies, basing on available data and guidelines. 
